IN8bio, Inc., a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, has reported strong progress in its Phase 1 and Phase 2 clinical programs, showing significant ...
Hosted on MSN
TC BioPharm reports progress in AML treatment trial
EDINBURGH, Scotland - TC BioPharm (Holdings) PLC (NASDAQ: TCBP), a biotechnology firm with a market capitalization of $33.08 million engaged in developing gamma-delta T cell therapies, announced today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback